Placental Cells Mitigate Radiation-Induced Complications in Mice, Hadassah Researchers Reveal
Placental cells, Hadassah Medical Organization researchers have shown, were successful in mitigating acute radiation-induced complications in mice when transplantation was initiated 24 hours following total body irradiation.
The research team from Hadassah's Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology studied two types of placental cells--pure maternal cell preparations (PLX-Mat) and a mixture of maternal ¬and fetal derived cells (PLX-RAD), developed by Pluristem Therapeutics, a leading developer of placenta-based cell therapies. Using intramuscular (IM) injections, they were able to overcome the difficulty experienced by other researchers whereby, with intravenous treatment, the stem cells became trapped mostly in the lungs immediately after administration. Rather, IM injections enabled them to easily deliver higher numbers of cells through multiple injections at different times.
Twenty four hours and five days after total body irradiation, the mice were treated with placental stromal cells (PLX). The researchers discovered that PLX-Mat increased the survival of the irradiation mice from 27 percent to 68 percent, while PLX-RAD cells increased the survival to 98 percent. The researchers found that they could delay the treatment with PLX-RAD up to 48 hours after irradiation with similar success. The study showed that the treated mice regained their weight significantly faster than did the few control survivors. Furthermore, the treatment stimulated extensive hematopoietic (blood producing) stem cell proliferation, which enabled the speedy recovery of the radiation-induced depleted bone marrow with a parallel increase in the number of circulating white blood cells, red blood cells, and platelets.
The Sharett Institute of Oncology is a world leader in cancer research. Its staff is at the cutting edge of treatment of breast and ovarian cancer, melanoma, lung and pancreatic cancer and leukemia.
The authors conclude: "Our study suggests that IM treatment with PLX-RAD cells may serve as a highly effective 'off the shelf' therapy to treat bone marrow failure following total body exposure to high doses of radiation." These cells can be stored, delivered frozen, and then defrosted just before injection.
The researchers add that they expect the treatment may also have major applications for clinical conditions associated with severe bone marrow aplasia, where blood cell development is impaired.
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>